Charles River Labs stock gains on growth inflection message

Published on 09/14/2026 at 18:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Labs stock is benefiting from management’s September 14, 2026 growth inflection comments at a Morgan Stanley healthcare conference. The shares are up strongly year-to-date and consensus EPS estimates for 2026 have risen in recent months.

Moderner CRO-Forschungscampus mit Glasfassade in Wilmington Massachusetts — Charles River Laboratories Forschungscampus in Wilmington Massachusetts, modernes Glaslaborgebäude, ISIN US1591881009, Außenansicht, Illustration mit AI erstellt.

Charles River Laboratories International Inc. stock (ISIN US1591881009) is drawing investor attention after management highlighted a growth inflection for the business at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, signaling better revenue growth, margin expansion and earnings ahead according to Investing.com.

Management points to a new growth phase

At the Morgan Stanley conference on September 14, 2026, Charles River Laboratories’ leadership described the company as entering a turning point where financial performance is expected to improve from the second half of 2026 onward, with stronger revenue growth, margin expansion and earnings per share improvement, as reported by Investing.com.

According to the same conference summary, management indicated that the company’s RMS segment is still expected to see a low single-digit percentage decline in 2026, but overall the group views 2026 as a transition year toward more robust growth and profitability in 2027, with DSA returning to organic growth in the second half of 2026 per Investing.com.

Analyst consensus and stock performance

The conference remarks come against a backdrop of strong share performance: Charles River Labs stock is up 36.9 percent year-to-date in 2026, according to a performance overview from Zacks.

Over the past three months, the consensus earnings per share estimate for Charles River Labs for the current year 2026 has increased by 2.6 percent, signaling that analysts have become more positive on the company’s near-term profitability as noted by Zacks.

Stock price and investor view

On the primary listing in the United States, Charles River Labs stock trades on the New York Stock Exchange in USD; recent data for 2026 show the shares supported by the strong year-to-date gain of 36.9 percent and by positive revisions to the EPS consensus for 2026, which together underline the market’s constructive view on the stock as of mid-September 2026 per Zacks.